Ulteriori informazioni
This book is the proceedings of the Falk Workshop on `Bile Acids in Hepatobiliary Disease', which took place at the Royal Society of Medicine (RSM) in London, UK, on 29-30 March 1999, and was held in association with the Section of Measurement in Medicine at the RSM.
The main interest in bile acid therapy has been recently in cholestatic liver disease. The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease. Leading world experts attempt to define its mechanism of action, and the current role of other non-surgical treatments in biliary disease. The physiology and pathogenesis of cholestatic and alcoholic liver disease and cholesterol gallstone disease is also examined.
Sommario
Preface. List of Contributors. 1. Introduction; T.C. Northfield. Section I: Cholestatic Liver Disease: Physiology, Pathogenesis and Epidemiology. 2. Cellular and Molecular Mechanisms of Bile Salt Transport in Health and Disease; J.L. Boyer. 3. Biochemical Aspects; J. Reichen. 4. Immunological Aspects; M.F. Bassendine. Section II: Bile Acid Therapy. 5. Optimum Dose of UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. 6. Ursodeoxycholic Acid - An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al. Section III: Clinical Trials. 7. Primary Biliary Cirrhosis: Long-Term Management with Ursodeoxycholic Acid; J. Heathcote. 8. Management of Patients with Primary Schlerosing Cholangitis; A. Stiehl. 9. Genetic Aspects; R. Thompson. 10. Congenital Defects in Bile Acid Synthesis Cause A Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease, and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. 11. Cystic Fibrosis of the Liver; C. Colombo. 12. Canalicular Secretion of Lysyl-fluorescein Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis: Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz. Section IV: Alcoholic and Other Liver Diseases. 13. Ethanol Metabolism; T. Peters. 14. Alcohol Abuse and Abstinence; H. Ghodse. 15. Pathogenesis of Alchoholic Liver Disease; C.S. Lieber. 16. Clinical Aspects of Alcoholic Liver Disease; R. Williams. Section V: Bile Acid Therapy. 17. Effect on Liver Function; P. Hayes. 18. Fibrosis Markers and Ursodeoxycholic Acid; J.M.C. Stenner. 19. Urdodeoxycholic Acid for Treatment of Chronic Hepatitis C: An `Interferon Sparing' Effect; A. Lanzini. Section VI: Cholesterol Gallstone Disease. 20. Pathogenesis of Cholesterol Gallstone Disease: Role of the Liver; M.C. Carey. 21. Pathogenesis of Gallstones: Events in Bile; T. Gilat. 22. Role of the Gallbladder in the Pathogenesis of Gallstone Disease; R.P. Jazrawi, et al. 23. The Role of the Large Intestine in Cholesterol Gallstone Formation; K.W. Heaton. 24. The Octreotide Model; R.H. Dowling. Section VII: Therapy. 25. Oral Bile Acid Therapy; E. Roda. 26. Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner. 27. Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. 28. Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. 29. Management of Gallstone Recurrence; T.C. Northfield. 30. Laparoscopic Cholecystectomy; A. Johnson. 31. Comparison of UDCA With Combination Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised Multicentre Trial; M.L. Petroni. Section VIII: Other Conditions. 32. Role of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A. Einarsson. 33. Role of Bile Acids in Colonic Neoplasia &endash; Human Studies; M. Stellini. Section IX: Chronic Pancreatitis. 34. Role of Bile Acids in Pancratic Steatorrhea; P. Zentler-Munro. 35. Impaired Uptake of Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric Patients with Cystic Fibrosis; H.J. Verkade. 36. Bile Acid Science (Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges for the Future; A.F. Hofmann. Index.
Riassunto
The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease.
